Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.

about

Survival impact of locoregional metachronous malignancy in survival of lung cancer patients who received curative treatment.

P2860

Q36948881-6BA6B875-406C-4126-B103-DD7B8E7BA08A

P2860

Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.

Item

http://www.wikidata.org/entity/Q38362871

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Immunostaining in lung cancer ...... d metastatic pulmonary tumors.

@en

type

Item

label

Immunostaining in lung cancer ...... d metastatic pulmonary tumors.

@en

prefLabel

Immunostaining in lung cancer ...... d metastatic pulmonary tumors.

@en

P1476

Immunostaining in lung cancer ...... d metastatic pulmonary tumors.

@en

P2093

Alyssa M Kraynie

http://www.w3.org/2001/XMLSchema#string

John M Carney

http://www.w3.org/2001/XMLSchema#string

Victor L Roggli

http://www.w3.org/2001/XMLSchema#string

P2860

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.

Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung.

The new World Health Organization classification of lung tumours.

p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.

Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance.

Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach.

Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma.

The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.

P304

429-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1513/ANNALSATS.201501-004FR

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25700114

http://www.w3.org/2001/XMLSchema#string

Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.

about

P2860

P2860

Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698